Obesity, Abdominal
Conditions
Brief summary
A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.
Interventions
DIETARY_SUPPLEMENTNAD+ precursor
NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)
OTHERPlacebo
Oral placebo daily intake for 6 months
Sponsors
University of Turku
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Willingness to provide informed consent to participate in the BATNAD study * Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent * Age 30-55 (sedentary lifestyle) * BMI = 18-25 kg/m2 (normal-weight subjects) * BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (subjects with obesity)
Exclusion criteria
* Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight \> 200 kg) * Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon) * Major alterations in the menstrual cycle (e.g., amenorrhea) * Use of nicotine based products * Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range) * Diabetes mellitus (fasting Hb1Ac \>6.5% or fasting glycaemia\> 7.0 mmol/) * Abnormal oral glucose tolerance test (2h OGTT \> 11.1 mmol/L) * Hypertension (blood pressure \> 160/100 mmHg) * Abnormal cardiovascular status (arrhythmia and/or long QTc in ECG, abnormal cardiac murmur, previous history of cardiovascular disease) * Abnormal coagulopathy (e.g., clotting abnormality) * Malignancies * Immunological, autoimmune and primary/secondary immunodeficiency disorders (including or not any active treatment) * Virus or bacterial infection (both asymptomatic and symptomatic picture) within the 45 days prior to the study start * Vaccination within the 45 days prior to the study start * Episode of fever or major surgery, burns and traumas within the month prior to the study start * Chronic infections requiring chronic antibiotic or anti-viral treatment * Whole blood donation in the last 3 months (\>400 mL of blood) or plans for blood donation during the entire protocol period * Weight change (intentional or not) over the last 6-months more than 5% of body weight, or plan to lose weight during the study * Allergy to lidocaine or epinephrine, or other local anaesthetics * Previous participation to studies where PET or CT method is used * Use of any medication that, in the opinion of local clinician/researcher, would negatively impact or mitigate full participation and completion, or could influence the study results. This especially applies to the use of β or α adrenergic receptors agonists/antagonists (e.g., β-blockers). * Any other cardiovascular, pulmonary, orthopaedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician/researcher, would preclude participation and successful completion of the protocol, or that would negatively impact or mitigate participation in and completion of the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Whole-body Insulin Sensitivity | 6 months | Whole-body insulin sensitivity measured with hyperinsulinemic, euglycemic clamp technique |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brown adipose tissue glucose uptake rate | 6 months | Brown adipose tissue glucose uptake rate will be measured with 18F-FDG PET-CT imaging |
Countries
Finland
Contacts
CONTACTMueez U-Din, PhD
CONTACTKirsi Virtanen, MD, PhD
PRINCIPAL_INVESTIGATORMueez U-Din, PhD
Turku PET Centre, Turku University Hospital
PRINCIPAL_INVESTIGATORKirsi A Virtanen, MD PhD
University of Turku
Outcome results
None listed